Cell Proliferation News and Research

RSS

UPR pathway helps tumor cells escape apoptosis during development of lymphoma

A pathway called the "Unfolded Protein Response," or UPR, a cell's way of responding to unfolded and misfolded proteins, helps tumor cells escape programmed cell death during the development of lymphoma.

21 Nov 2012

Scientists identify cell growth pathway that is unusually active in gliomas

Insights from a genetic condition that causes brain cancer are helping scientists better understand the most common type of brain tumor in children.

17 Nov 2012

Researchers describe structure of active site core of topoisomerase II alpha anti-cancer drug target

A group of researchers at the University of California, Berkeley have for the first time described the structure of the active site core of topoisomerase II alpha, an important target for anti-cancer drugs.

15 Nov 2012

Glycemic load raises colon cancer recurrence risk

Increased glycemic loads and high carbohydrate consumption may increase the risk for colon cancer recurrence, show the results of a US study.

8 Nov 2012

Stapled Peptide oncology drug candidate exhibits robust efficacy in xenograft cancer models

Aileron Therapeutics, Inc. and its collaborator Roche today announced new results of a preclinical study of its Stapled Peptide oncology drug candidate ATSP-7041, which exhibited robust efficacy in MDM2 and MDMX xenograft cancer models.

8 Nov 2012

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Taiho Pharmaceutical Co., Ltd., the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies.

7 Nov 2012

Vitamin D deficiency: an interview with Kellie Bilinski

We know that vitamin D is important in keeping bones strong. In the last 30-40 years it has also been realized that vitamin D has a lot of other roles in the body. Vitamin D essentially has a role in any cell in the body that has a vitamin D receptor.

5 Nov 2012

Nisin may slow or prevent squamous cell head and neck cancers

Nisin, a common food preservative, may slow or stop squamous cell head and neck cancers, a University of Michigan study found.

1 Nov 2012

Botanical treatment holds hope for triple-negative breast cancer

A unique formula made from medicinal mushrooms, traditional Chinese herbs and other natural ingredients inhibits aggressive, human triple-negative breast cancer and breast-to-lung metastasis in mice. This is the third peer-reviewed study to demonstrate the botanical formula's anticancer effects.

29 Oct 2012

Sea water strengthens the body against viruses, low defences, bacteria and pathogens

Sea water therapy is a technique of cellular nutrition backed by more than 100 years of clinical use in hospitals, during which numerous studies have demonstrated its beneficial effects on patients' health.

29 Oct 2012

Researchers identify genes that control regeneration of the intestine in planarian flatworms

Researchers report in the journal Developmental Cell that they have identified genes that control growth and regeneration of the intestine in the freshwater planarian Schmidtea mediterranea.

26 Oct 2012

New book focuses on Wnt signaling

Wnt proteins are signaling molecules that play critical roles during embryonic development and in the regeneration of adult tissues. They bind to Frizzled and LRP family receptors on the cell surface, triggering a series of events that cause beta-catenin to enter the nucleus and activate transcription factors that control cell fate and cell proliferation. Mutations in components of the Wnt pathway lead to developmental defects and are common in cancer.

19 Oct 2012

Research may lead to new ways to identify women with breast cancer risks from low-dose radiation

Scientists from the U.S. Department of Energy's Lawrence Berkeley National Laboratory have identified tissue mechanisms that may influence a woman's susceptibility or resistance to breast cancer after exposure to low-dose ionizing radiation, such as the levels used in full-body CT scans and radiotherapy.

18 Oct 2012

Recurrent patterns of genomic imbalances determine evolution of invasive breast cancer

Ductal carcinoma in situ (DCIS) is considered a precursor lesion for invasive breast cancer if untreated, and is found in approximately 45% of patients with invasive ductal carcinoma (IDC). Patients with DCIS only (not accompanied by invasive disease) have a 5-year-survival of nearly 100%, compared to 89% for all stages of invasive breast cancer (24% for patients with distant metastasis).

17 Oct 2012

Cigarette smoke adversely affects the developing human airway

Research presented at the ANESTHESIOLOGY 2012 annual meeting revealed cigarette smoke adversely affects the developing human airway, especially in prematurity. Fetuses and premature babies exposed to cigarette smoke are at greater risk for developing childhood respiratory diseases, such as asthma.

16 Oct 2012

NFKB1 gene variant may reduce risk of lung cancer

A variant in a gene involved with inflammation and the immune response is linked with a decreased risk of lung cancer. That is the finding of an analysis published early online in CANCER, a peer-reviewed journal of the American Cancer Society. The results add to the growing body of literature implicating these processes in the development of lung cancer.

8 Oct 2012

$Stent fracture after stent implantation linked to thrombosis$

Stent fracture after stent implantation linked to thrombosis

Stent fracture after everolimus-eluting stent implantation occurs in 2.9% of lesions and is associated with a significantly increased rate of major adverse cardiac events, say researchers.

2 Oct 2012

F-18-FLT-PET predicts early response to chemoradiotherapy in head and neck cancer

Determining the optimal treatment course and predicting outcomes may get easier in the future for patients with head and neck sqaumous cell carcinomas (HNSCCs) with the use of an investigational imaging agent.

2 Oct 2012

Addition of ficlatuzumab to gefitinib may be effective in select subsets of patients with NSCLC

AVEO Oncology today announced that detailed results from an exploratory, randomized Phase 2 study evaluating the combination of ficlatuzumab, the company's HGF inhibitory antibody, and gefitinib compared to gefitinib monotherapy in previously untreated Asian subjects with non-small cell lung cancer (NSCLC) were presented at the 2012 Congress of the European Society for Medical Oncology (ESMO).

1 Oct 2012

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Eli Lilly and Company today announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC).

1 Oct 2012

Cell Proliferation News and Research

UPR pathway helps tumor cells escape apoptosis during development of lymphoma

Scientists identify cell growth pathway that is unusually active in gliomas

Researchers describe structure of active site core of topoisomerase II alpha anti-cancer drug target

Glycemic load raises colon cancer recurrence risk

Stapled Peptide oncology drug candidate exhibits robust efficacy in xenograft cancer models

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Vitamin D deficiency: an interview with Kellie Bilinski

Nisin may slow or prevent squamous cell head and neck cancers

Botanical treatment holds hope for triple-negative breast cancer

Sea water strengthens the body against viruses, low defences, bacteria and pathogens

Researchers identify genes that control regeneration of the intestine in planarian flatworms

New book focuses on Wnt signaling

Research may lead to new ways to identify women with breast cancer risks from low-dose radiation

Recurrent patterns of genomic imbalances determine evolution of invasive breast cancer

Cigarette smoke adversely affects the developing human airway

NFKB1 gene variant may reduce risk of lung cancer

Stent fracture after stent implantation linked to thrombosis

F-18-FLT-PET predicts early response to chemoradiotherapy in head and neck cancer

Addition of ficlatuzumab to gefitinib may be effective in select subsets of patients with NSCLC

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News